中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
5期
311-314
,共4页
褚金曼%杜咏梅%骆树瑜%李蕊%董瑞
褚金曼%杜詠梅%駱樹瑜%李蕊%董瑞
저금만%두영매%락수유%리예%동서
腺样囊性癌%EZH2%Ki-67%表观遗传学
腺樣囊性癌%EZH2%Ki-67%錶觀遺傳學
선양낭성암%EZH2%Ki-67%표관유전학
salivary adenoid cystic carcinoma%EZH2%Ki67%epigenetics
目的：研究人涎腺腺样囊性癌组织中EZH2（enhancer of zeste homolog2）和Ki-67的表达及其相关性。方法：采用免疫组织化学染色法，检测石蜡包埋的42例涎腺腺样囊性癌（salivary adnoid cystic carcinoma，SACC）及5例正常涎腺组织中，多梳组蛋白EZH2和细胞周期蛋白Ki-67的表达水平，分析与临床病理特征之间的关系并探讨二者的相关性。结果：EZH2在腺样囊性癌组织中的表达显著高于正常涎腺组织（P<0.05），EZH2表达阳性率66.67%（28/42），EZH2表达与肿瘤病理分型及临床分期相关，而与性别、年龄、发病部位不相关，而在5例正常涎腺组织中不表达。在Ki-67阳性的33例腺样囊性癌患者中，25例EZH2表达阳性，表达率75.76%（25/33），Ki-67阴性表达的9例中，3例EZH2表达阳性，表达率33.33%（3/9），两者比较差异有统计学意义（P<0.05）。结论：EZH2在腺样囊性癌中表达增加且与肿瘤细胞的增殖密切相关，提示腺样囊性癌中EZH2通过其在细胞周期管理中的作用，参与肿瘤细胞的增殖过程。
目的：研究人涎腺腺樣囊性癌組織中EZH2（enhancer of zeste homolog2）和Ki-67的錶達及其相關性。方法：採用免疫組織化學染色法，檢測石蠟包埋的42例涎腺腺樣囊性癌（salivary adnoid cystic carcinoma，SACC）及5例正常涎腺組織中，多梳組蛋白EZH2和細胞週期蛋白Ki-67的錶達水平，分析與臨床病理特徵之間的關繫併探討二者的相關性。結果：EZH2在腺樣囊性癌組織中的錶達顯著高于正常涎腺組織（P<0.05），EZH2錶達暘性率66.67%（28/42），EZH2錶達與腫瘤病理分型及臨床分期相關，而與性彆、年齡、髮病部位不相關，而在5例正常涎腺組織中不錶達。在Ki-67暘性的33例腺樣囊性癌患者中，25例EZH2錶達暘性，錶達率75.76%（25/33），Ki-67陰性錶達的9例中，3例EZH2錶達暘性，錶達率33.33%（3/9），兩者比較差異有統計學意義（P<0.05）。結論：EZH2在腺樣囊性癌中錶達增加且與腫瘤細胞的增殖密切相關，提示腺樣囊性癌中EZH2通過其在細胞週期管理中的作用，參與腫瘤細胞的增殖過程。
목적：연구인연선선양낭성암조직중EZH2（enhancer of zeste homolog2）화Ki-67적표체급기상관성。방법：채용면역조직화학염색법，검측석사포매적42례연선선양낭성암（salivary adnoid cystic carcinoma，SACC）급5례정상연선조직중，다소조단백EZH2화세포주기단백Ki-67적표체수평，분석여림상병리특정지간적관계병탐토이자적상관성。결과：EZH2재선양낭성암조직중적표체현저고우정상연선조직（P<0.05），EZH2표체양성솔66.67%（28/42），EZH2표체여종류병리분형급림상분기상관，이여성별、년령、발병부위불상관，이재5례정상연선조직중불표체。재Ki-67양성적33례선양낭성암환자중，25례EZH2표체양성，표체솔75.76%（25/33），Ki-67음성표체적9례중，3례EZH2표체양성，표체솔33.33%（3/9），량자비교차이유통계학의의（P<0.05）。결론：EZH2재선양낭성암중표체증가차여종류세포적증식밀절상관，제시선양낭성암중EZH2통과기재세포주기관리중적작용，삼여종류세포적증식과정。
Objective:This study aimed to investigate the expressions of EZH2 and Ki-67 in the salivary adenoid cystic carcino-ma (SACC) of humans and their correlation. Methods:A total of 42 cases of SACC tumor tissues and 5 cases of normal tissues were considered to determine the expressions of EZH2 and Ki-67 by immunohistochemistry. The relationship and correlation of such expres-sions with the clinicopathological characteristics were also analyzed. Results:The expression of EZH2 was notably higher in SACC than in normal tissues (P<0.05). EZH2 expression was detected in 66.67%(28/42) of the tumor tissues. This expression was correlated with pathological grade and clinical stage. By contrast, EZH2 expression did not correlate with gender, age, and localization. EZH2 was not expressed in normal tissues. The incidence of EZH2 expression in the Ki-67 positive group was 75.76%(25/33) and the incidence in the Ki-67 negative group was 33.33%(3/9). The difference between the two groups was statistically significant (P<0.05). Conclu-sion:The increased expression of EZH2 in SACC was related to tumor proliferation. EZH2 may participate in tumor cell proliferation via cell cycle management.
